The conversation about heart health often focuses on cholesterol numbers, blood pressure readings, and family history—and all of those things matter. But there’s a major cardiovascular risk factor that’s less often discussed in routine care, and it’s one of the most modifiable: insulin resistance. The connection between insulin resistance and heart disease runs through multiple physiological pathways, and it begins long before any formal diabetes diagnosis. For patients who’ve been told their bloodwork is ‘mostly normal,’ insulin resistance can be quietly accumulating cardiovascular damage in the background.
Many patients who come to SustainMD have been managing cardiovascular risk factors—elevated blood pressure, borderline cholesterol, weight around the midsection—as if they were separate, unrelated problems. What’s rarely been explained to them is that these conditions frequently share a common upstream driver: insulin resistance and the metabolic dysfunction it creates. Treating each condition in isolation is less effective than addressing the metabolic root cause that ties them together.
Dr. Allison Barbee, MD, is board-certified in both internal medicine and obesity medicine, which positions her to evaluate cardiovascular and metabolic risk as an integrated picture rather than separate boxes to check. SustainMD provides telehealth care to patients in North Carolina, California, Florida, and Maine, bringing this level of cardiometabolic evaluation to patients who may not otherwise have access to a physician who treats these conditions as a connected system.
How Insulin Resistance Creates Cardiovascular Risk
The Atherogenic Lipid Profile
One of the most important cardiovascular effects of insulin resistance is the change it produces in blood lipids—and not necessarily in the direction that standard cholesterol panels catch. Insulin resistance drives up triglycerides (fatty acids in the bloodstream), drives down HDL cholesterol (the protective type), and shifts LDL cholesterol toward smaller, denser particles that are more dangerous to artery walls. This is sometimes called the ‘atherogenic dyslipidemia’ pattern, and it’s common in patients with insulin resistance and metabolic syndrome.
Standard lipid panels report total LDL as a single number, which can appear reassuringly normal even when the proportion of small, dense LDL is elevated. Patients with insulin resistance may have ‘normal’ LDL on a basic panel while carrying a significantly higher cardiovascular risk than that number suggests. More detailed lipid analysis—including particle size and non-HDL cholesterol—provides a more accurate cardiovascular risk picture for these patients.
For patients managing weight alongside cholesterol concerns, SustainMD’s weight loss for high cholesterol program addresses the metabolic contributors to lipid abnormalities as part of a comprehensive cardiovascular metabolic treatment plan.
Endothelial Dysfunction and Arterial Inflammation
The inner lining of blood vessels—the endothelium—plays a critical role in cardiovascular health by regulating blood vessel tone, preventing clot formation, and controlling inflammatory responses. Insulin resistance impairs endothelial function through several pathways: it reduces the production of nitric oxide (which keeps vessels relaxed and dilated), promotes inflammatory signaling within vessel walls, and increases adhesion molecule expression that allows inflammatory cells to stick to and penetrate artery walls.
This process—endothelial dysfunction and subsequent arterial inflammation—is one of the earliest steps in atherosclerosis, the progressive buildup of plaque inside arterial walls that leads to heart attacks and strokes. The timeline here is important: endothelial dysfunction can be present and progressing for years or even decades before any clinical event, which is why treating insulin resistance early has genuine cardioprotective value.
Chronic Inflammation and Oxidative Stress
Insulin resistance, particularly when visceral fat is present, creates a sustained low-grade inflammatory state. Visceral fat cells secrete pro-inflammatory molecules—including TNF-alpha, interleukin-6, and C-reactive protein—that affect blood vessels throughout the body. This chronic inflammation promotes atherosclerosis, damages arterial walls, and impairs the immune regulation that normally limits plaque formation.
- Elevated C-reactive protein (CRP) is a measurable marker of this systemic inflammation and is independently associated with cardiovascular risk—separate from traditional risk factors like cholesterol. Patients with insulin resistance often have elevated CRP that improves with metabolic treatment.
- Oxidative stress—an imbalance between damaging free radicals and the body’s antioxidant defenses—is elevated in insulin resistance and contributes to endothelial damage, LDL oxidation (which makes it more dangerous to arteries), and impaired vascular repair. Reducing oxidative stress through metabolic improvement has cardiovascular benefits beyond what lipid-lowering medications alone provide.
Hypertension and Sympathetic Nervous System Activation
As discussed in other SustainMD content, insulin resistance drives elevated blood pressure through multiple mechanisms: sodium retention, RAAS activation, and increased sympathetic nervous system tone. Sustained sympathetic nervous system activation—a state of chronic physiological alertness—has independent cardiovascular effects: it elevates heart rate, increases vascular resistance, promotes arrhythmias, and places ongoing strain on the heart that accumulates over time.
This is particularly relevant for patients with metabolic syndrome, which combines insulin resistance, abdominal obesity, elevated blood pressure, atherogenic dyslipidemia, and impaired fasting glucose. Metabolic syndrome is associated with a two- to threefold increase in cardiovascular event risk compared to patients without it—and the risk is greater than the sum of its individual components.
SustainMD’s metabolic syndrome treatment program addresses these interconnected risk factors as a unified metabolic problem rather than separate conditions requiring separate management.
The Timeline: How Cardiovascular Damage Accumulates
One of the most important things to understand about insulin resistance and heart health is that the damage begins accumulating early—often years or decades before any clinical event. Endothelial dysfunction is measurable in people in their 20s with significant insulin resistance. Arterial stiffness begins to increase as insulin resistance progresses. The atherogenic lipid pattern promotes plaque buildup continuously, not just when risk thresholds are crossed on paper.
This long preclinical phase is actually the greatest opportunity for intervention. Treating insulin resistance before cardiovascular damage has become advanced can slow, halt, or in some cases partially reverse the arterial changes that accumulate over time. Waiting until a heart attack or significant arterial disease is present forfeits this window. The asymptotic progression of insulin resistance—where a patient feels reasonably well despite significant metabolic dysfunction—is one of the main reasons early screening and treatment matter.
What Effective Cardiometabolic Treatment Looks Like
Treating insulin resistance with cardiovascular risk in mind requires attention to several components simultaneously. Weight reduction—particularly visceral fat loss—improves every component of the cardiovascular risk picture: lipids, blood pressure, inflammatory markers, and endothelial function. Even modest weight loss of 5 to 10 percent of body weight produces measurable cardiovascular benefits in patients with insulin resistance.
Dietary approaches that reduce glycemic load and include anti-inflammatory foods (olive oil, fatty fish, vegetables, nuts, legumes) directly address both the metabolic and inflammatory dimensions of cardiovascular risk. Regular aerobic and resistance exercise improves insulin sensitivity, reduces visceral fat, lowers triglycerides, and improves endothelial function through mechanisms that are partly independent of weight loss.
- GLP-1 receptor agonists—including semaglutide—have demonstrated cardiovascular outcome benefits in clinical trials beyond their effect on weight and blood sugar. Semaglutide has FDA approval for reducing cardiovascular events in patients with obesity and established cardiovascular disease, making it a particularly relevant option for patients with both insulin resistance and elevated cardiovascular risk.
- Statin therapy may be indicated alongside metabolic treatment for patients with significantly elevated cardiovascular risk or elevated LDL. However, statins treat one component of the cardiovascular risk picture; they don’t address insulin resistance, atherogenic dyslipidemia, inflammation, or blood pressure independently.
For patients ready to address cardiometabolic risk through a physician-supervised metabolic program, SustainMD’s medical weight loss and metabolic health programs provide the comprehensive evaluation and treatment framework that cardiometabolic risk requires.
Frequently Asked Questions
1. Can insulin resistance cause heart disease?
Yes. Insulin resistance is one of the major modifiable cardiovascular risk factors, contributing to heart disease through multiple mechanisms including atherogenic dyslipidemia, hypertension, endothelial dysfunction, chronic inflammation, and sympathetic nervous system activation. These effects accumulate over time before any clinical event.
2. How does insulin resistance affect cholesterol levels?
Insulin resistance typically drives up triglycerides, lowers HDL cholesterol, and shifts LDL toward smaller, denser particles that are more damaging to artery walls. This pattern—atherogenic dyslipidemia—may not be fully captured by a standard lipid panel if only total LDL is reported.
3. What is the connection between metabolic syndrome and heart disease?
Metabolic syndrome—which includes insulin resistance, abdominal obesity, elevated blood pressure, atherogenic lipids, and elevated fasting glucose—is associated with a two- to threefold increase in cardiovascular event risk. Treating metabolic syndrome comprehensively reduces this risk more effectively than treating each component independently.
4. Does losing weight reduce cardiovascular risk from insulin resistance?
Yes. Meaningful weight loss—particularly visceral fat reduction—improves multiple cardiovascular risk factors simultaneously: blood pressure, triglycerides, HDL, inflammatory markers, and insulin sensitivity. Even modest weight loss in the range of 5 to 10 percent of body weight produces clinically significant cardiovascular benefits.
5. Are GLP-1 medications good for heart health?
Research supports cardiovascular benefits of GLP-1 medications beyond their effects on weight and blood sugar. Semaglutide has demonstrated significant reductions in cardiovascular events in patients with obesity and established cardiovascular disease in clinical trials, and has FDA approval for this indication. Your physician can assess whether this is appropriate for your situation.
6. How does visceral fat damage the heart?
Visceral fat is metabolically active and secretes inflammatory molecules that affect the cardiovascular system throughout the body—promoting arterial inflammation, impairing endothelial function, raising blood pressure, and worsening the lipid profile. Its proximity to internal organs also means the liver receives a particularly high concentration of these inflammatory signals.
7. Is high triglycerides related to insulin resistance?
Yes. Elevated triglycerides are one of the most consistent metabolic signs of insulin resistance. Insulin normally inhibits triglyceride release from the liver; when insulin resistance is present, this suppression fails and triglycerides accumulate in the bloodstream. Elevated fasting triglycerides are a useful clinical marker of underlying insulin resistance.
8. Can treating insulin resistance prevent heart attacks?
Research supports that treating insulin resistance—through weight loss, metabolic improvement, lifestyle change, and when appropriate, medications—reduces cardiovascular event risk. This isn’t a guarantee, but the evidence for cardiometabolic risk reduction through insulin sensitizing treatment is clinically significant.
9. What does CRP have to do with insulin resistance?
C-reactive protein (CRP) is a marker of systemic inflammation that is frequently elevated in insulin resistance, particularly when visceral fat is present. Elevated CRP is independently associated with increased cardiovascular risk and can serve as a useful monitoring marker as metabolic treatment progresses—improvement in CRP reflects reduction in the inflammatory burden that contributes to cardiovascular damage.
10. Can SustainMD help with both metabolic health and cardiovascular risk?
Yes. Dr. Barbee’s background in internal medicine encompasses cardiovascular risk management, and SustainMD’s programs address metabolic health and cardiovascular risk as connected conditions. Patients with insulin resistance, metabolic syndrome, and elevated cardiovascular risk benefit from the integrated cardiometabolic evaluation that SustainMD provides via telehealth in North Carolina, California, Florida, and Maine.
Disclaimer
This content is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making decisions about your health. Treatment recommendations vary based on individual circumstances, medical history, and clinical evaluation.
